A Study of JNJ-64281802 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

December 11, 2022

Study Completion Date

December 11, 2022

Conditions

Healthy

Interventions

DRUG

JNJ-64281802

JNJ-64281802 tablets will be administered orally as per the defined regimens.

Trial Locations (1)

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY